Pet owners know that our furry friends are part of the family. We strive to provide them with a happy and healthy life. Sadly, roughly one in four dogs will be diagnosed with cancer in their lifetime.  Mosaic is developing a new immunotherapy for the treatment of cancers that afflict dogs and other companion animals. Studies performed by veterinarians in the U.S. and abroad have shown antitumor activity and safety when utilizing our unique in situ vaccine candidate, MIE-201, in canine companion animals. Mosaic is advancing this new cancer-fighting immune stimulant for the treatment of multiple tumor types with the goal of improving the lives of the pets we love.